Luteal Phase Support using Oral Dydrogesterone-a Prospective Treatment for Future Replacing Micronized Vaginal Progesterone

Abstract

Although micronized vaginal progesterone is the accepted norm for use in luteal phase support (LPS) in controlled ovarian stimulation (COS) that is used for in vitro fertilization (IVF) cycles, recently importance of oral Dydrogesterone has got the importance in lieu of its oral availability, cheap, no cumbersome side effects and no definitive newer fetal side effects. After the LOTUS 1 trial with a multicenter double placebo, double dummy design it has proved an equal efficacy if not superiority of oral D, over micronized vaginal progesterone and it seems D might soon become the standard of care for LPS in conventional IVF cycles besides its routine indication for recurrent abortions. A potent orally active progesterone receptor agonist D was developed in the1950’s. Structurally it is 6-dehyro-9β,10α-progest (figure 1). It has been used for multiple disorders like premenstrual syndrome [1], cycle irregularity [2], endometriosis [3], habitual abortion [4], along with for post-menopausal hormone therapy [5], since its advent. Advantages of D and its active metabolite, 20hydroxy D, is that unlike other progesterone (P) member family, they do not have any relevant clinically, agonistic or antagonistic activity on either androgen, estrogen and glucocorticoid receptors and have only mild mineralocorticoid properties [6-8]. Main advantage from other synthetic P’s is lack of androgenic side effects like hirsutism, voice changes, acne etc. and no masculinizing changes in the fetus. Because of safety concerns in view of cross-receptor activation has prevented use of a majority of progestins during fertility therapy and pregnancy.

Authors and Affiliations

Kulvinder Kochar Kaur, Gautam Allahbadia, Mandeep Singh

Keywords

Related Articles

Infertility Caused by Jinn

The World of Jinn is both sinister and intriguing. Their supernatural power (invisible in their natural state, shape-shifter, flying around the World in a second, illusion creation, possibility to possess the...

Advances in Adenomyosis Diagnosis Utilizing Transvaginal Ultrasonography-A Short Summary

Adenomyosis is a frequent condition, being present in 20% of general gynae population [1,2] and 30-40% of those attending assisted reproductive technology clinics, having a detrimental effect on cases of in vi...

Breast Cancer Awareness

As an Ob & Gyn, member of National Breast Cancer Foundation and a woman I find it very important to raise awareness about the importance of early detection of Breast Cancer. Make a difference! Spread the word about mammo...

Schistosomahaematobium and Urogenital Disorders

Concerning Europe, we are in the presence of a re-introduction of this disease, since it had been recorded in Portugal, where several foci had occurred in Algarve-Southern Portugal [2,3] Still in Euro...

Sleep and Menopause: Review

Sleep consists of REM and non-REM (rapid eye movement) periods that happen cyclically. Each one lasts between 90 to 120 minutes, and in one night there are approximately 4 to 6 cycles. During the first half of the night,...

Download PDF file
  • EP ID EP638866
  • DOI 10.32474/OAJRSD.2018.01.000119
  • Views 96
  • Downloads 0

How To Cite

Kulvinder Kochar Kaur, Gautam Allahbadia, Mandeep Singh (2018). Luteal Phase Support using Oral Dydrogesterone-a Prospective Treatment for Future Replacing Micronized Vaginal Progesterone. Open Access Journal of Reproductive System and Sexual Disorders, 1(4), 97-102. https://www.europub.co.uk/articles/-A-638866